Condition
Abruptio Placentae
Total Trials
7
Recruiting
0
Active
0
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
28.6%
2 terminated out of 7 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
14%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results60% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Completed3
Terminated2
Unknown1
Withdrawn1
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT03782168TerminatedPrimary
Plasma Concentration of Biological Markers in Placental Abruption
NCT04558996Unknown
Spanish Registry of Pregnant Women With COVID-19
NCT00014989Phase 3Completed
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
NCT01279369Terminated
The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta
NCT00186069Not ApplicableCompletedPrimary
Magnesium Sulfate vs Placebo for Placental Abruption
NCT01501890Not ApplicableWithdrawn
Progesterone for First Trimester Vaginal Bleeding
NCT01068795Not ApplicableCompleted
Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
Showing all 7 trials